Popular Articles

The Importance Of Medicaid Continuity For Former Inmates
It is time for states to suspend, rather than terminate, the Medicaid benefits of inmates while they are incarcerated, say correctional health care experts from The Miriam Hospital in a commentary published online by the Journal of General Internal Medicine.
drugs without prescription
Faculty Of Translational Medicine Boosts Support For Biomedical Researchers
A new Faculty of Translational Medicine has been launched to increase support for, and enhance collaboration among researchers as they search for new treatments and diagnostic tests for a range of diseases and conditions. The Faculty is based in the National Institute for Health Research Comprehensive Biomedical Research Center at Guy"s and St Thomas" hospitals and King"s College London.
News of the day
Editorial, Opinion Piece Respond To Closure Of Murdered Abortion Provider Tiller's Clinic
Two newspapers recently published an editorial and an opinion piece in reaction to the announcement that murdered Kansas abortion provider George Tiller"s Wichita clinic would be permanently closed. The clinic was one of a handful in the U.S. offering abortion procedures in the second and third trimesters. Summaries appear below.~ Kansas City Star: The closing of Tiller"s clinic is "a tragedy for American democracy," and the "irrational violence" of his death has "trumped public policy," a Star editorial states. "The basis of civilization is that we agree to submit to the rule of law in order for society to flourish," the editorial says, adding that Tiller"s murder is "antithetical to that principle. It is dismaying to see a killer achieve his objective." The editorial notes that Tiller provided abortion services in "tragic cases" involving women "at risk of infertility or death; fetuses with severe abnormalities; and victims of rape and incest." It continues that the "reduction or loss of that service will create hardships and may put women"s lives at risk." Hospitals and doctors who refer such cases to abortion providers "must reassess the circumstances under which they would perform late-term abortions," according to the editorial. In addition, the "medical profession must take a role in training and supporting doctors willing to provide abortions," and the government and local police "must do all they can to protect a legal medical practice," the editorial says. It concludes, "Democracy demands that we not allow murder to make de facto public policy" (Kansas City Star, 6/11).~ Eric Zorn, Chicago Tribune: The announcement that Tiller"s clinic will remain permanently closed "was simply more proof that violence and intimidation can get results where civil discourse and political process fail," Tribune columnist Zorn writes. "The question isn"t whether prominent foes of abortion rights are being honest with us when they decry Tiller"s violent death and express regret over the means used to achieve an end they"ve sought," Zorn writes, adding, "Some are, I"m sure." He continues that abortion-rights opponents "recognize that ... a movement calling itself "pro-life"can"t also be pro-murder" and "are politically savvy enough to know that the gains won by terrorist acts are grudging and difficult to sustain." He continues that to "make terrorism less effective, and thereby discourage it," abortion-rights advocates, the medical profession, politicians and law enforcement officials "need to reopen that clinic in Wichita and assure its safe operation ... to defy terrorism, if for no other reason." He concludes that "as long as abortion remains legal, this same coalition needs to strive to expand the number of facilities where it"s available" (Zorn, Chicago Tribune, 6/11).
Sexual Health

First-Line Nab-Paclitaxel Is Superior To Docetaxel For Metastatic Breast Cancer

CHICAGO, May 26, 2009 - New data show that nab-paclitaxel (AbraxaneR for Injectable Suspension) prolongs investigator-assessed, median progression-free survival (PFS) by almost seven months versus the highest standard dose of docetaxel in women with metastatic breast cancer. Nab-paclitaxel is a novel albumin-bound paclitaxel, an established chemotherapy agent, combined with albumin, a very small naturally-occurring protein. The findings, from a phase 2 trial that enrolled 302 women with previously untreated metastatic breast cancer, were published online today in the Journal of Clinical Oncology (JCO). "We believe that the results suggest that weekly nab-paclitaxel may be a suitable alternative to the taxane docetaxel given every three weeks for the first-line treatment of metastastic breast cancer," principal investigator William J. Gradishar, MD, Director of Breast Medical Oncology at Northwestern University"s Robert H. Lurie Comprehensive Cancer Center, said. In prior research involving metastatic breast cancer patients, nab-paclitaxel had produced significantly higher anti-tumor activity than solvent-based paclitaxel. The present study was undertaken to evaluate the efficacy and safety of three nab-paclitaxel dosing regimens (weekly versus every three weeks) and to examine differences in safety and efficacy between these dosing regimens of nab-paclitaxel and docetaxel administered at the highest standard dose. Patients were randomized to receive nab-paclitaxel 300 mg/m2 every three weeks (q3w), 100 mg/m2 weekly, 150 mg/m2 weekly, or docetaxel 100 mg/m2 q3w. Results showed that patients treated with nab-paclitaxel 150 mg/m2 weekly had a significantly longer median PFS than docetaxel-treated patients when assessed by both the independent radiologists (12.9 versus 7.5 months, respectively, p=0.0065) and the investigator (14.6 months versus 7.8 months, respectively, p=0.012) using RECIST guidelines. The overall response rate (ORR) tended to be higher with both weekly nab-paclitaxel regimens than docetaxel by independent radiology review. The investigator assessment found that the difference in ORR between both weekly nab- paclitaxel doses and docetaxel was statistically significant. Review by both the investigator and the independent radiologist found a significantly higher disease control rate (DCR) in patients receiving either dose of weekly nab-paclitaxel compared to docetaxel. All nab-paclitaxel doses showed an overall superior safety and toxicity profile over docetaxel. Dr. Gradishar said that the results of this study bolster earlier data identifying a role for nab-paclitaxel as a suitable option to docetaxel for first-line treatment of metastatic breast cancer. The study was sponsored by Abraxis BioScience, Inc. in Los Angeles, California. Written by Jill Stein Jill Stein is a Paris-based freelance medical writer. jillstein03(at)gmail.com Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):